1 active not recruiting, 1 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Penile Squamous Cell Carcinoma: new trials by email Literature Review of Penile Squamous Cell Carcinoma trials Research Report on Penile Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas EVOLVE104 - Bladder Cancer, Squamous Cell Carcinoma of the Lung | Phase 1 | Recruiting | EvolveImmune United, Inc | 160 | 2025-11-13 | 2026-09-15 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 152 | 2015-07-22 | 2026-10-15 |
Urinary Bladder Neoplasms (2) · Anus Neoplasms (1) · Carcinoma, Renal Cell (1) · Esophageal Squamous Cell Carcinoma (1) · Penile Neoplasms (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1) · Urogenital Neoplasms (1)
Carcinoma (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Urinary Bladder Diseases (2) · Urogenital Diseases (2) · Urologic Diseases (2) · Urologic Neoplasms (2) · Adenocarcinoma (1) · Anus Diseases (1) · Carcinoma, Squamous Cell (1)
Biopsy (1) · CTLA-4 Antigen (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Specimen Handling (1) · cabozantinib (1)
EvolveImmune United, Inc (1) · National Cancer Institute (NCI) (1)
United States (2)
Andrea B Apolo (1)
PMID 32915679, PMID 35031545, PMID 38954785
UM1CA186712 (1), UM1CA186716 (1), UM1CA186717 (1), ZIABC011078 (1)